Latest Combimatrix Corp (CBMX) Headlines
CombiMatrix Hires R. Weslie Tyson, M.D., as Chief Medical Officer
GlobeNewswire - Mon Mar 10, 5:00AM CDT
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that veteran pediatric pathologist R. Weslie Tyson, M.D. (Wes), has been hired as Chief Medical Officer, effective April 8, 2014. Dr. Tyson, 56, will report directly to CombiMatrix President and CEO Mark McDonough.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 06, 12:39PM CST
These under-$10 stocks look ready to trade higher from current levels.
CombiMatrix to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 5:22AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that CEO Mark McDonough is scheduled to present at the 26 Annual ROTH Conference on Wednesday, March 12, 2014 at 11:30 am Pacific Time. The conference is being held at the Ritz-Carlton in Dana Point, California on March 9-12, 2014.
Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine
CombiMatrix Corporation Reports Results for 2013 Fourth Quarter and Full Year
GlobeNewswire - Wed Feb 19, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, reported today that total revenues for the fourth quarter and twelve months ended December 31, 2013 increased to $1.75 million and $6.37 million, respectively, up 18 percent and 19 percent from the comparable periods in 2012, respectively. Revenues from the Company's core prenatal microarray testing markets grew by 57 percent in the fourth quarter of 2013 over the corresponding period in 2012, and by 112 percent year-over-year. Sequentially, prenatal microarray testing revenues grew by 22% from the third quarter of 2013 to the fourth quarter. Prenatal microarray volumes grew by 74 percent and 126 percent in the fourth quarter and twelve months ended December 31, 2013, respectively, from the comparable periods in 2012. Billable prenatal microarray tests were 674 and 2,222 for the three and twelve months ended December 31, 2013, both of which represent record prenatal microarray volumes for the Company.
CombiMatrix Reiterates Previously Reported Terms of Nasdaq Listed Warrants (Symbol: CBMXW)
GlobeNewswire - Wed Feb 12, 1:30PM CST
Due to recent trading activity in CombiMatrix Corporation's (Nasdaq:CBMX) publicly listed warrants, symbol CBMXW, the Company would like to reiterate the terms of said warrants.
CombiMatrix Corporation to Release Fourth Quarter Financial Results on February 19, 2014
GlobeNewswire - Wed Feb 12, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its fourth quarter 2013 financial results on Wednesday, February 19, 2014. Results will be released prior to trading on that day.
CombiMatrix Announces Contract With Galaxy Health Network
GlobeNewswire - Thu Jan 23, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has entered into a contractual agreement with Galaxy Health Network for coverage of CombiMatrix's diagnostic laboratory services.
CombiMatrix to Participate in the RedChip Emerging Growth Showcase
GlobeNewswire - Fri Jan 17, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that CEO Mark McDonough is scheduled to participate in the RedChip Emerging Growth Showcase at 2:00 pm EST on Thursday, January 23, 2014, at www.redchip.com. The showcase, a digital conference, is being held January 22-23, 2014.
CombiMatrix Announces Partnership With ProPath to Provide Products of Conception Testing
GlobeNewswire - Tue Jan 14, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has been selected by ProPath(R) to provide its chromosomal microarray analysis (CMA) testing for miscarriage analysis for ProPath patients. ProPath, based in Dallas, is a wholly physician-owned provider of pathology services to clinicians, hospitals, reference laboratories and medical facilities nationwide.
5 Stocks Poised for Breakouts
at The Street - Fri Jan 10, 12:20PM CST
These stocks look ready to break out and trade higher from current levels.
10-Q: HELEN OF TROY LTD
Edgar Online - Thu Jan 09, 3:10PM CST
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Pandora and Twitter are big market movers
AP - Mon Jan 06, 3:21PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Molecular Diagnostics Role in Cancer Testing Analyzed in In-demand TriMark Report Published at MarketPublishers.com
PRWeb - Mon Jan 06, 1:52PM CST
Nowadays, molecular diagnostics (MD) represents a promising area of research and medicine, which is witnessing tremendous technology advancements alongside the emergence of novel applications. The range of technologies associated with MD includes, amid others, gene expression profiling using microarrays, DNA probes, next-generation signal detection, first-generation amplification, fluorescent in-situ hybridization (FISH), second-generation microfluidics and biochips, and biosensors and molecular labels. These technologies are essential tools playing vital roles in the optimization of drug therapy, in the discovery of new therapeutic molecules for cancer as well as in the screening, classification and diagnosis of cancer patients. Presently, MD for cancer testing is deemed as the most lucrative area for innovations and growth.
CombiMatrix Corporation enters into network deal with FedMed of Gaithersburg, Maryland
M2 - Tue Dec 24, 8:34AM CST
Molecular diagnostics company CombiMatrix Corporation (NasdaqCM:CBMX) reported on Monday the execution of a contractual agreement for coverage of its diagnostic laboratory services with FedMed.
CombiMatrix Announces Contract With FedMed National Provider Network
GlobeNewswire - Mon Dec 23, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has entered into a contractual agreement for coverage of its diagnostic laboratory services with FedMed, a national provider network and healthcare financial services organization.
Cancana Announces Binding Term Sheet on Financing With The Sentient Group and Acquisition of Rio Madeira
Marketwire Canada - Fri Dec 20, 3:01PM CST
Cancana Resources Corp. (TSX VENTURE:CNY) (the "Company" or "Cancana") announces today the execution of a binding term sheet, (the "Agreement"), with Ferrometals BV, ("Ferrometals"), in connection with the acquisition of Rio Madeira Comercio Importacao E Exportacao De Minerios, ("Rio Madeira"), and proposed financings of up to an aggregate of C$6.25 million in Cancana.
CombiMatrix Closes $12 Million Underwritten Public Offering
GlobeNewswire - Fri Dec 20, 8:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has closed its previously announced firm commitment underwritten public offering of 12,000 units of Series D convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. Each unit consists of one share of Series D convertible preferred stock, which is convertible into 485.4369 shares of common stock at a conversion price of $2.06 per share, and one warrant to purchase 485.4369 shares of common stock at an exercise price of $3.12 per share. The net proceeds from the sale of the units, after deducting underwriting discounts and commissions and offering expenses payable by the Company, are anticipated to be approximately $10.8 million.
CombiMatrix Prices $12 Million Underwritten Public Offering
GlobeNewswire - Tue Dec 17, 8:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has priced a firm commitment underwritten public offering of 12,000 units of Series D convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. Each unit consists of one share of Series D convertible preferred stock, which is convertible into 485.4369 shares of common stock at a conversion price of $2.06 per share, and one warrant to purchase 485.4369 shares of common stock at an exercise price of $3.12 per share. The net proceeds from the sale of the units, after deducting underwriting discounts and commissions and offering expenses payable by the Company, are anticipated to be approximately $10.8 million.
CombiMatrix Hires R. Weslie Tyson, M.D., as Chief Medical Officer
GlobeNewswire - Mon Mar 10, 5:00AM CDT
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that veteran pediatric pathologist R. Weslie Tyson, M.D. (Wes), has been hired as Chief Medical Officer, effective April 8, 2014. Dr. Tyson, 56, will report directly to CombiMatrix President and CEO Mark McDonough.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 06, 12:39PM CST
These under-$10 stocks look ready to trade higher from current levels.
CombiMatrix to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 5:22AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that CEO Mark McDonough is scheduled to present at the 26 Annual ROTH Conference on Wednesday, March 12, 2014 at 11:30 am Pacific Time. The conference is being held at the Ritz-Carlton in Dana Point, California on March 9-12, 2014.
Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine
CombiMatrix Corporation Reports Results for 2013 Fourth Quarter and Full Year
GlobeNewswire - Wed Feb 19, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, reported today that total revenues for the fourth quarter and twelve months ended December 31, 2013 increased to $1.75 million and $6.37 million, respectively, up 18 percent and 19 percent from the comparable periods in 2012, respectively. Revenues from the Company's core prenatal microarray testing markets grew by 57 percent in the fourth quarter of 2013 over the corresponding period in 2012, and by 112 percent year-over-year. Sequentially, prenatal microarray testing revenues grew by 22% from the third quarter of 2013 to the fourth quarter. Prenatal microarray volumes grew by 74 percent and 126 percent in the fourth quarter and twelve months ended December 31, 2013, respectively, from the comparable periods in 2012. Billable prenatal microarray tests were 674 and 2,222 for the three and twelve months ended December 31, 2013, both of which represent record prenatal microarray volumes for the Company.
CombiMatrix Reiterates Previously Reported Terms of Nasdaq Listed Warrants (Symbol: CBMXW)
GlobeNewswire - Wed Feb 12, 1:30PM CST
Due to recent trading activity in CombiMatrix Corporation's (Nasdaq:CBMX) publicly listed warrants, symbol CBMXW, the Company would like to reiterate the terms of said warrants.
CombiMatrix Corporation to Release Fourth Quarter Financial Results on February 19, 2014
GlobeNewswire - Wed Feb 12, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its fourth quarter 2013 financial results on Wednesday, February 19, 2014. Results will be released prior to trading on that day.
CombiMatrix Announces Contract With Galaxy Health Network
GlobeNewswire - Thu Jan 23, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has entered into a contractual agreement with Galaxy Health Network for coverage of CombiMatrix's diagnostic laboratory services.
CombiMatrix to Participate in the RedChip Emerging Growth Showcase
GlobeNewswire - Fri Jan 17, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that CEO Mark McDonough is scheduled to participate in the RedChip Emerging Growth Showcase at 2:00 pm EST on Thursday, January 23, 2014, at www.redchip.com. The showcase, a digital conference, is being held January 22-23, 2014.
CombiMatrix Announces Partnership With ProPath to Provide Products of Conception Testing
GlobeNewswire - Tue Jan 14, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has been selected by ProPath(R) to provide its chromosomal microarray analysis (CMA) testing for miscarriage analysis for ProPath patients. ProPath, based in Dallas, is a wholly physician-owned provider of pathology services to clinicians, hospitals, reference laboratories and medical facilities nationwide.
5 Stocks Poised for Breakouts
at The Street - Fri Jan 10, 12:20PM CST
These stocks look ready to break out and trade higher from current levels.
10-Q: HELEN OF TROY LTD
Edgar Online - Thu Jan 09, 3:10PM CST
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Pandora and Twitter are big market movers
AP - Mon Jan 06, 3:21PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
Molecular Diagnostics Role in Cancer Testing Analyzed in In-demand TriMark Report Published at MarketPublishers.com
PRWeb - Mon Jan 06, 1:52PM CST
Nowadays, molecular diagnostics (MD) represents a promising area of research and medicine, which is witnessing tremendous technology advancements alongside the emergence of novel applications. The range of technologies associated with MD includes, amid others, gene expression profiling using microarrays, DNA probes, next-generation signal detection, first-generation amplification, fluorescent in-situ hybridization (FISH), second-generation microfluidics and biochips, and biosensors and molecular labels. These technologies are essential tools playing vital roles in the optimization of drug therapy, in the discovery of new therapeutic molecules for cancer as well as in the screening, classification and diagnosis of cancer patients. Presently, MD for cancer testing is deemed as the most lucrative area for innovations and growth.
CombiMatrix Corporation enters into network deal with FedMed of Gaithersburg, Maryland
M2 - Tue Dec 24, 8:34AM CST
Molecular diagnostics company CombiMatrix Corporation (NasdaqCM:CBMX) reported on Monday the execution of a contractual agreement for coverage of its diagnostic laboratory services with FedMed.
CombiMatrix Announces Contract With FedMed National Provider Network
GlobeNewswire - Mon Dec 23, 5:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has entered into a contractual agreement for coverage of its diagnostic laboratory services with FedMed, a national provider network and healthcare financial services organization.
Cancana Announces Binding Term Sheet on Financing With The Sentient Group and Acquisition of Rio Madeira
Marketwire Canada - Fri Dec 20, 3:01PM CST
Cancana Resources Corp. (TSX VENTURE:CNY) (the "Company" or "Cancana") announces today the execution of a binding term sheet, (the "Agreement"), with Ferrometals BV, ("Ferrometals"), in connection with the acquisition of Rio Madeira Comercio Importacao E Exportacao De Minerios, ("Rio Madeira"), and proposed financings of up to an aggregate of C$6.25 million in Cancana.
CombiMatrix Closes $12 Million Underwritten Public Offering
GlobeNewswire - Fri Dec 20, 8:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has closed its previously announced firm commitment underwritten public offering of 12,000 units of Series D convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. Each unit consists of one share of Series D convertible preferred stock, which is convertible into 485.4369 shares of common stock at a conversion price of $2.06 per share, and one warrant to purchase 485.4369 shares of common stock at an exercise price of $3.12 per share. The net proceeds from the sale of the units, after deducting underwriting discounts and commissions and offering expenses payable by the Company, are anticipated to be approximately $10.8 million.
CombiMatrix Prices $12 Million Underwritten Public Offering
GlobeNewswire - Tue Dec 17, 8:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has priced a firm commitment underwritten public offering of 12,000 units of Series D convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. Each unit consists of one share of Series D convertible preferred stock, which is convertible into 485.4369 shares of common stock at a conversion price of $2.06 per share, and one warrant to purchase 485.4369 shares of common stock at an exercise price of $3.12 per share. The net proceeds from the sale of the units, after deducting underwriting discounts and commissions and offering expenses payable by the Company, are anticipated to be approximately $10.8 million.
